关键词：克罗恩病；消化；胃肠道；炎症；回肠炎；肉芽肿性；肠炎；结肠炎
摘 要：CD is a type of IBD that causes inflammation of the digestive or GI tract. The disease is also known as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. Though the exact etiology of the disease is unknown, it usually causes ulceration in the small intestine and the opening of the large intestine. It can originate in any part of the GI tract from the mouth to the anus. CD can affect people of any age; however, teenagers and individuals in their twenties are more prone to it.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

06.1 Understanding the Disease

06.2 Etiology

06.2.1 Autoimmune Reaction

06.2.2 Genes

06.2.3 Environment

06.3 Stages of CD

06.4 Epidemiology

06.4.1 Worldwide Prevalence of CD

06.4.2 US

06.4.3 UK

06.5 Symptoms

06.5.1 Diarrhea

06.5.2 Fever and Fatigue

06.5.3 Abdominal Pain and Cramping

06.5.4 Perianal Disease and Blood in Stool

06.5.5 Reduced Appetite and Weight Loss

06.6 Diagnosis and Testing

06.6.1 Early Tests and Exams

06.6.2 Endoscopy and Biopsy

06.6.3 Chromoendoscopy

06.6.4 Small Intestinal Imaging

06.7 Treatment

06.7.1 Medication .

06.7.2 Diet and Nutrition

06.7.3 Surgery

07. CD Pipeline Landscape

07.1 Some Emerging Therapeutic Options

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 CD Market in US

08.3.1 Market Size and Forecast

08.4 CD Market in Japan

08.4.1 Market Size and Forecast

08.5 Five Forces Analysis

09. Market Segmentation by Drug Class

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2014

18.2.1 AbbVie

18.2.2 AstraZeneca

18.2.3 Biogen Idec

18.2.4 Johnson & Johnson

18.2.5 Takeda Pharmaceutical

18.2.6 UCB

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 AbbVie

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Product Segmentation by Revenue 2013

19.1.4 Product Segmentation by Revenue 2012 and 2013

19.1.5 Sales by Geography

19.1.6 Business Strategy

19.1.7 Key Developments

19.1.8 SWOT Analysis

19.2 AstraZeneca plc

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Segmentation by Revenue 2013

19.2.4 Business Segmentation by Revenue 2011-2013

19.2.5 Sales by Geography

19.2.6 Business Strategy

19.2.7 Key Developments

19.2.8 SWOT Analysis

19.3 Biogen Idec

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Business Segmentation by Revenue 2013

19.3.4 Geographical Segmentation by Revenue 2013

19.3.5 Business Strategy

19.3.6 Key Developments

19.3.7 SWOT Analysis

19.4 Johnson & Johnson

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation by Revenue 2013

19.4.4 Business Segmentation by Revenue 2012 and 2013

19.4.5 Geographical Segmentation by Revenue 2013

19.4.6 Business Strategy

19.4.7 Recent Developments

19.4.8 SWOT Analysis

19.5 Takeda Pharmaceuticals

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation by Revenue 2013

19.5.4 Business Segmentation by Revenue 2013

19.5.5 Geographical Segmentation by Revenue 2013

19.5.6 Business Strategy

19.5.7 Recent Developments

19.5.8 SWOT Analysis

19.6 UCB

19.6.1 Key Facts

19.6.2 Business Overview

19.6.3 Product Segmentation by Revenue 2013

19.6.4 Product Segmentation by Revenue 2012 and 2013

19.6.5 Geographical Segmentation by Revenue 2013

19.6.6 Business Strategy

19.6.7 Recent Developments

19.6.8 SWOT Analysis

20. Other Reports in this Series